The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CV-1808     (3R,4S,5R)-2-(6-amino-2- phenylazanyl-purin...

Synonyms: CHEBI:131139, KST-1A5658, AC1Q4XYC, AR-1A4396, LS-181920, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CV 1808


High impact information on CV 1808


Biological context of CV 1808

  • Using 5 nM [3H]CV 1808, unlabeled CV 1808 produced shallow inhibition curves in all three brain areas, with 61 to 75% of the binding displaying IC50 values of 16 to 24 nM, whereas the remaining 28 to 37% of binding had lower affinity (IC50 595-1130 nM) [10].
  • 3. The rank order of agonist potency to reduce the rate of peristalsis was: N6-cyclopentyladenosine (CPA) > NECA > R(-)-N6-(2-phenylisopropyl)adenosine (R-PIA) > chloroadenosine (2-CADO) > S-PIA > 2-phenylaminoadenosine (CV-1808) [11].
  • If [3H]CGS 21680 is used for ice-cold assays, or if either [3H]CV 1808 or [3H]CGS 21680 are used for assays at 21 degrees C, the potency order of competing compounds changes markedly and becomes characteristic of A2a adenosine receptor binding sites; CGS 15943 > or = CGS 21680 congruent to NECA > CGS 22988 > or = CV 1808 [12].
  • The ED50 values for pulmonary vasodilation were 1.9 x 10(-8) mol/L for 5'-N-ethylcarboxamidoadenosine (NECA), 4.5 x 10(-8) mol/L for 2-phenylaminoadenosine (CV-1808), 2.6 x 10(-6) mol/L for R(-)-N6-(2-phenylisopropyl) adenosine (R-PIA), and 6.5 x 10(-6) mol/L for cyclopentyladenosine, results consistent with an adenosine A2 receptor [13].

Anatomical context of CV 1808


Associations of CV 1808 with other chemical compounds


Gene context of CV 1808


Analytical, diagnostic and therapeutic context of CV 1808

  • The topical administration of CV-1808 produced a rapid rise in IOP, with a maximum increase of 15.6 +/- 1.6 mm Hg [5].
  • In the present study, the antinociceptive effects after intrathecal injection of each of 6 N6-substituted adenosine analogs and of 2-phenylaminoadenosine were compared with the affinity for the A1- and A2-adenosine receptors [20].
  • Quantitation of 6-amino-2-phenylamino-9-beta-D-ribofuranosyl-9-H-purine (CV-1808) and its metabolite, 2-(2-hydroxyphenyl)aminoadenosine, in human serum and urine by high performance liquid chromatography using a fluorimetric detector [21].
  • During intravenous infusion of CV-1808 (0.25 and 0.5 microgram/kg/min for 10 min) the ST-segment elevation in the epicardial ECG induced by a 5-min occlusion of a coronary arterial branch was occasionally enhanced in association with cardiac acceleration [3].


  1. Direct cutaneous hyperalgesia induced by adenosine. Taiwo, Y.O., Levine, J.D. Neuroscience (1990) [Pubmed]
  2. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. Tanabe, M., Terashita, Z., Nishikawa, K., Hirata, M. J. Cardiovasc. Pharmacol. (1984) [Pubmed]
  3. Effect of 2-phenylaminoadenosine (CV-1808) on ischemic ST-segment elevation in anesthetized dogs. Matsumoto, N., Kawazoe, K., Tanabe, M., Imamoto, T., Fujiwara, S., Hirata, M. J. Cardiovasc. Pharmacol. (1981) [Pubmed]
  4. Modulation of intraocular pressure by adenosine agonists. Crosson, C.E., Gray, T. Journal of ocular pharmacology. (1994) [Pubmed]
  5. Characterization of ocular hypertension induced by adenosine agonists. Crosson, C.E., Gray, T. Invest. Ophthalmol. Vis. Sci. (1996) [Pubmed]
  6. Adenosine and 2-phenylaminoadenosine (CV-1808) inhibit human neutrophil bactericidal function. Hardart, G.E., Sullivan, G.W., Carper, H.T., Mandell, G.L. Infect. Immun. (1991) [Pubmed]
  7. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Kull, B., Arslan, G., Nilsson, C., Owman, C., Lorenzen, A., Schwabe, U., Fredholm, B.B. Biochem. Pharmacol. (1999) [Pubmed]
  8. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Dionisotti, S., Ongini, E., Zocchi, C., Kull, B., Arslan, G., Fredholm, B.B. Br. J. Pharmacol. (1997) [Pubmed]
  9. 125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE. Hussain, T., Linden, J., Mustafa, S.J. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  10. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. Cornfield, L.J., Hu, S., Hurt, S.D., Sills, M.A. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  11. Functional characterization of the adenosine receptor mediating inhibition of peristalsis in the rat jejunum. Hancock, D.L., Coupar, I.M. Br. J. Pharmacol. (1995) [Pubmed]
  12. Comparison of A4 and A2a binding sites in striatum and COS cells transfected with adenosine A2a receptors. Luthin, D.R., Linden, J. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  13. Adenosine produces pulmonary vasodilation in the perfused rabbit lung via an adenosine A2 receptor. Pearl, R.G. Anesth. Analg. (1994) [Pubmed]
  14. Adenosine receptor activation modulates intraocular pressure in rabbits. Crosson, C.E. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  15. Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography. Johansson, B., Fredholm, B.B. Neuropharmacology (1995) [Pubmed]
  16. A2a/D2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D2 and adenosine A2a receptor cDNA. Snaprud, P., Gerwins, P., Caron, M.G., Libert, F., Persson, H., Fredholm, B.B., Fuxe, K. Biochem. Pharmacol. (1994) [Pubmed]
  17. Interaction of 2-phenylaminoadenosine (CV 1808) with adenosine systems in rat tissues. Taylor, D.A., Williams, M. Eur. J. Pharmacol. (1982) [Pubmed]
  18. Adenosine receptors are coupled negatively to release of tachykinin(s) from enteric nerve endings. Christofi, F.L., McDonald, T.J., Cook, M.A. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  19. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Heffner, T.G., Wiley, J.N., Williams, A.E., Bruns, R.F., Coughenour, L.L., Downs, D.A. Psychopharmacology (Berl.) (1989) [Pubmed]
  20. The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor. Karlsten, R., Post, C., Hide, I., Daly, J.W. Neurosci. Lett. (1991) [Pubmed]
  21. Quantitation of 6-amino-2-phenylamino-9-beta-D-ribofuranosyl-9-H-purine (CV-1808) and its metabolite, 2-(2-hydroxyphenyl)aminoadenosine, in human serum and urine by high performance liquid chromatography using a fluorimetric detector. Hayashi, Y., Miyake, S., Kuwayama, M., Hattori, M., Usui, Y. Chem. Pharm. Bull. (1982) [Pubmed]
WikiGenes - Universities